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A B S T R A C T
Epithelioid hemangioendothelioma (EHE) is a rare tumor of the vascular origin. It was first described in its pulmo-
nary form by Dail and Leibow in 1975. and named »intravascular bronhioalveolar tumor« (IVBAT). Since then, reports
of occurences of the tumor have been made for number of locations, but most often tumor can be found in soft tissues,
liver, lungs, bone and skin. It is considered to be a low or borderline malignant tumor with, usually, slow progression,
but aggressive forms have been descrided. We here report a case of a 46-year old female patient with multifocal malignant
tumor spreading to lungs, liver, spleen and with synchronous involvement of lumbal vertebrae, illiac bones and central
nervous system dissemination. To the best of the authors knowledge, no case of malignant EHE with multiorgan involve-
ment of this proportions and synchronous central nervous system and bone involvement in one patient has been reported
to this date in English-speaking literature.
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Introduction
Epithelioid hemangioendothelioma is a rare vascular
neoplasm of uncertain malignant potential. It was first
described in its pulmonary form by Dail and Leibow in
1975. Due to its characteristic appearance and propen-
city to invade pulmonary blood vessels and small airways
authors named it »intravascular bronchioalveolar tu-
mor« (IVBAT) considering it to be an aggressive form of
bronchioalveolar carcinoma1. Further immunohistoche-
mistry and electron microscopy studies proved IVBAT to
be of vascular endothelial origin, therefore Weiss and
Enzinger renaming the tumor epithelioid hemangioen-
dothelioma in 19822.
Due to low incidence and low diagnosis rate there is, in
recent years, constantly growing knowledge of possible
causes, pathophysiological pathways that lead to the
tumorogenesis and disease development along with know-
legde of biological nature of the tumor. There is till an un-
met need for randomised clinical trials that would help
elucidate the clinical questions on the effective treatment
procedures that would increase the progression free sur-
vival or may offer a possibility of cure to the patients.
Case Report
A 46-year old female patent was referred due to her
complaints of sharp, colic-like pain in her upper abdomen
and occassional diarrhea in April 2004. Patient also com-
plained of pain in her lumbar spine that radiated to her
sacrum. That symptom existed for 5 months but was
greatly intensified in two months ahead of admission.
She also stated she felt fatigue and lethargy for the last 5
months with frequent urinary infections and subfebrile
temperatures of up to 37.6°C. She had lost 7 kilograms
during one year before admission. In patient history she
revealed that 17 years ago she was evaluated in hospital
because of radiographic finding of lung changes for which
toracotomy was done and biopsy specimen taken. Ac-
cording to the patient, a rare form of semi-malignant
process was diagnosed for which she received no therapy
and had no follow up. Other patient’s medical history
was unremarkable.
Initial laboratory findings revealed sideropenic ane-
mia and elevated erythrocite sedimentation rate of 100.
Other laboratory unremarkable. Using esophagogastro-
duodenoscopy a diagnosis of chronic gastritis with positive
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H. pylori test and acute bulbitis was made so the patient
was introduced to the triple therapy (pantoprazolum,
amoxicilin i metronidazolum) for eradication of H.pylori.
Colonoscopy was performed and results were satisfac-
tory, all stool exams for bacteria and parasites negative.
Tumor markers (CEA, CA 19-9, AFP, CA 125, CA 15-3)
also came out negative. As a result of therapy, abdominal
pain subsided, but lumbar pain remained, so the medical
workup continued. Chest radiography revealed promi-
nent interstitial pattern close to the base of the lungs
with calcified tuberculous sequelae infraclavicularly.
Computed tomography (CT) of the thorax showed multi-
ple bilateral nodular lesions in the lung parenchyma
measuring less than 15 milimeters in diameter (Figure
1a). Abdominal CT showed an ill-defined hypodense le-
sion in the upper pole of the spleen measuring 20 mili-
meters in diameter along with two smaller lesions of the
equal presentation in the middle pole, both 10 milime-
ters in diameter (Figure 1b). A 10 milimeter calcified le-
sion was revealed in the left lobe of the liver. Abdominal
CT also detected well vascularized soft-tissue mass mea-
suring 30x15 milimeter destructing the bone structure of
both L2 and L3 vertebrae (Figure 1c). Abdominal mag-
netic resonance (MRI) confirmed CT findings as it was
expected, but it revealed an additional lesion 2 mili-
meters in diameter located subcapsular in left liver lobe
not seen on CT. MRI of the lumbar spine was performed
to evaluate vertebral dissemination. Hyperintense signal
was revealed within the L2, L3, L5, and S2 vertebrae
along with both iliac bones (Figure 1d).
Patient was transfered to neurosurgery where verte-
brosynthesis was performed and biopsy specimen af the
disease-altered bone was obtained. Hystologic evaluation
revealed existance of round, polygonal, and in parts of
the specimen spindle shaped cells, arranged both in cords
and nests that showed striking atypia. Abundant eosino-
philic cytoplasms contained intracytoplasmic lumina oc-
casionally occupied by erythrocites. Immunostains re-
vealed diffuse positivity for CD31, CD34 and vimetnin
with negativity for keratins. Diagnosis of the EHE was
therefore made (Figure 2). During her stay in clinic, pa-
tient complained on headaches and forgetfullness. MRI
of the brain disclosed two metastatic deposits in the left
cerebral hemisphere. One was located frontoparietaly
measuring 16x13 milimeters, accompanied with exten-
sive perifocal edema and mass effect on adjacent struc-
tures, including ventricular system, and the other nod-
ule, located temporoposteriorly was only 4–5 milimeters
large (Figure 3).
Chemotherapy regiment with carboplatin and etopo-
side with addition of interferon a-2a was started, only to
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Fig. 1. a) Computed tomography scan of the chest shows multiple bilateral nodules of varying sizes; b) Abdominal MRI: axial T2-weighted
image demonstrates focal splenic lesion with high signal intensity (arrow); c) Abdominal MRI: coronal T2-weighted image (gradient-echo) of
the abdomen delineates area of high signal intensity in the body of L3 vertebrae (arrowhead); d) Axial T2-weighted image (gradient-echo)
of the L3 vertebrae reveals hyperintense lesions in the right part of the body (arrow) and left articular and transverse process (arrowhead).
establish continuous disease progression through reeval-
uation of the disease six weeks later. Repeated brain MRI
after 2 months displayed progression of the disease de-
tecting new lesions. Abdominal CT 5 months after show-
ed disease progression – spleen nodules enlargement
with appearance of new lesions. Between the stomack,
pancreatic tail and spleen a conglomerate of enlarged
lymphatic nodes appeared, as well as a new mass adja-
cent to the pancreas measuring 5 centimeters in diame-
ter that was indentified as a metastasis. Patient’s clinical
condition rapidly deteriorated leading to her death 6
months after the diagnosis has been established.
Discussion
Epithelioid hemagioendothelioma is a very rare type
of tumor with, up to today, unestablished incidence and
unknown etiology and less than 500 reported cases world-
wide. It is included in the group of vascular tumors origi-
nating from epithelioid or histiocytoid endothelial cell
representing 1% of all vascular neoplasms. Usually is
considered to be a tumor of low to borderline malignancy
following an unpredictable clinical course. In most cases
clinical course in mainly intermediate, one between hae-
mangioma and angiosarcoma although cases of very ag-
gressive expression of tumor have been reported in lite-
rature3,4. It is commonly affecting middle-aged patients
although it can be found in all age groups – several cases
have been reported in pediatric patients5,6 and it shows
female predominance3.
EHE is usualy found accidentaly since majority of pa-
tients are either asymptomatic or have unspecific signs
or only mild symptoms in time of diagnosis such as
cough, sputum, chest pain or dyspnea in case of pulmo-
nary EHE5,7; right upper quadrant pain and weight loss,
nausea, weakness and fatigue in hepatic EHE8; paresis of
the limbs, seasures, visual disturbances, even intracere-
bral hemorrhage in cerebral EHE4,9,10. Several studies
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Fig. 2. a) Infiltration of epitheloid haemangioendothelioma in lumbar vertebra, b) Histologic feature with typical strand or cord-like
pattern, and intracytoplasmic lumina (arrow). (B) Atypical tumor cells positive for CD34.
Fig. 3. a) Brain MRI: gadolinium-enhanced T1-weighted axial image of the brain shows enhancing nodular frontoparietal lesion (ar-
rowhead) with associated hypointense perifocal edema (asterisk); b) Coronal T2 weighted image demonstrates round lesion with inter-
mediate signal intensity surrounded by a significant amount of hyperintense perifocal edema and mass effect to the ventricular system.
tried to identify parameters that would help predict the
biologic behaviour and clinical outcome of EHE but re-
sults have not been entirely conclusive and unified. Mi-
totic activity (>1 or >3 mitoses per 50 high power fields
depending on the study), size (> 3.0 cm in diametar), cel-
lular atypia, necrosis, high cellularity and extensive spin-
dling are features that have reached statistical signifi-
cance in some studies (but not in all) and may help
differentiate tumors that should be regarded as aggre-
sive and treated as such from the day of diagnosis, from
those that could be designated low– risk and for which a
good prognosis is anticipated3,4,9,11. Symptoms at presen-
tation, hepatic metastases, peripheral lymphadenopathy
and lymphangitic spread of tumor are also prognostic
factors indicating increased mortality in a number of
studies3,4,7,9,11. Tumor can arise from almost any organ
but is most commonly located in soft tissues, liver, lungs,
bones and skin. It can be manifested as an unicentric or
multicentric disease of a single organ or as a multiorgan
disease, weather it is presented simultaneously or se-
quencially. In latter, it is difficult to prove if tumor is
multicentric or there is a primary lesion with multiple
organ metastasis3,5,11. Prognosis is often uncertain becouse
of unspecific behaviour shown by EHE that seams to
elude all efforts to evaluate it with greater amount of cer-
tainty using prognostic factors and for which EHE has
been rightfully refeared to as a »clinical chameleon«12.
Reports have been made of patients living from several
months after diagnosis has been established, up to 30
years, sometimes even with extensive parenchymal in-
volvement3,7 with expected survival between 1–20 years
and intermediate clinical course.
Presented here is a case of a disseminated EHE affect-
ing patient’s lungs, liver, spleen, lymph nodes, lumbo-
sacral vertebral collumn, illiac bones and central nervous
system. This extent of multiorgan involvement, espe-
cially with synchronous central nervous system and bone
dissemination, to the best of the authors knowledge, has
not been reported nor described in literature till now.
Questions remain unanswered weather this is the case of
synchronous or sequential organ involvement as well as
weather this is the case where the tumor remained dor-
mant through 17 years and then transformed into ag-
gresive, malignant form disseminating in mentioned lo-
cations13,14. Typically, histology of EHE reveals clusters
of rounded or slightly spindled eosinophilic endothelial
cells arranged in nests or cords. Tumor cells have abun-
dant eosinophylic cytoplasms filled with numerous intra-
cellular vacuols. Any mitotic figures are not a character-
istic finding for EHE, but their presence, as already
mentioned, is a predictor of an unfavourable outcome.
Immunohistochemical stains of EHE cases show posi-
tivity for CD34, CD31, factor VIII-RAg and vimetin3,10,11.
Negativity of epithelial marker cytokeratin is essential to
exclude tumors of the epithelial origin, although small
percentage of EHE tend to coexpress makers of both en-
dothelial and epithelial origin 3.
In our case diagnosis was based on histological and
immunohistochemical evidence as well as radiological
findings of typical multiple pulmonary nodules. Cellular
atypia, symptoms at presentation and metastatic spread
spoke in favour of high malignant potential as well as
fulminant course of the disease confirmed by fierce pro-
gression registered by control cerebral MR performed in
2 months period and abdominal CT performed in 6
months period, spoke in favour of high malignant poten-
tial and aggressive nature of the tumor described.
Due to rarety of the tumor and specific tumor biology
no standard therapy has been established to this day.
Several spontaneous remissions have been reported and
only anegdotal examples of remissions due to applied
therapy. Surgical excision of a localized disease has the
greatest shown benefit and should be considered as the
treatment of choice although such approach has limited
merit in a disseminated setting3,14. In asymptomatic pa-
tients as well as in patients with successfull surgical tu-
mor resection regular follow up must be performed. EHE
are chemo- and radioresistant tumors15. In case of a
widespread disease, several chemotherapy protocols us-
ing numerous cytostatic agents have been reported with
a single case of complete remission16 and several cases of
small results or none. Immunotherapy using interferon a
has shown contraversial results ranging from partial
response17 to stable disease. Report has been made on pa-
tient with hepatic EHE with pulmonary metastasis who
was successfully treated with talidomide18. Controlled
clinical trials are needed to determine clinical benefits
from those types of treatment19,20.
Conclusion
Epithelioid hemangioendothelioma is vascular tumor
regarded to be of low malignant potential. Malignant
variants are extremely rare. In the presented case tumor
malignancy is demonstrated by multiorgan dissemina-
tion, rapid progression and histological finding of atypia.
Based on the presented case and available literature it is
opinion of the authors that the usual designation of EHE
as a low-grade tumor has to be reevaluated and more
controled clinical studies to present unified prognostic
criteria have to be performed keeping in mind other
known entities such as gastrointestinal stromal tumors
that have proven, as well as EHE, to potentially have
very unfavourable clinical forms. Differentiation param-
eters between multicentric versus metastatic tumor ori-
gins cases of multiple tumor sites is still to be clarified.
Also, controlled clinical trials that may indicate effective
treatment options are much needed.
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AGRESIVNI MULTIFOKALNI OBLIK EPITELOIDNOG HEMANGIOENDOTELIJOMA:
PRIKAZ SLU^AJA
S A @ E T A K
Epitelioidni hemangioendoteliom (EHE) je vrlo rijedak tumor vaskularnog podrijetla. Deil i Leibow su 1975. godine
prvi put opisali njegov pulmonalni oblik i nazvali ga »intravaskularni bronhoalveolarni tumor« (IVBAT). Nakon toga se
u literaturi opisuje pojavnost tumora u mekim tkivima, jetri, plu}ima, kostima i ko`i. Iako se smatra tumorom niskog ili
grani~no malignog potencijala sa, uglavnom, sporom progresijom, opisani su i agresivni oblici. Ovdje je prikazan slu~aj
46-godi{nje bolesnice kod koje je maligni tumor multifokalno zahvatio plu}a, jetru, slezenu, lumbalne kralje{ake, ilija~ne
kosti i sredi{nji `iv~ani sustav. Koliko je autorima poznato, do sada u literaturi engleskog govornog podru~ja nije objav-
ljen slu~aj malignog EHE sa multiorganskom zahva~eno{}u ovakvih razmjera i vrlo agresivnog tijeka.
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